FDA, HHS and USDA Serve Up Ultra-Processed Food RFI

July 25, 2025

Reading Time : 1 min

On July 25, the U.S. Food and Drug Administration (FDA), in collaboration with the U.S. Department of Health and Human Services (HHS) and U.S. Department of Agriculture (USDA), unveiled the highly anticipated joint request for information on ultra-processed foods (UPFs). Specifically, the administration is seeking information and data to help develop a uniform definition for UPFs in the U.S. food supply.

This information request is part of the broader Make America Healthy Again (MAHA) initiative and focuses on concerns about health impacts of UPFs including links to chronic diseases such as cardiovascular disease, obesity and type 2 diabetes. The request for information (RFI) comes as several states move to advance regulations targeting food additives and UPFs.

Currently, there is no universally accepted definition of UPFs. A uniform definition is likely to serve as the foundation for future regulatory actions, including potential changes to product labeling and marketing standards.

The RFI solicits input on a range of topics, including:

  • Existing Classification Systems: What existing classifications systems or policies should be considered, and what are their strengths and limitations?
  • Ingredient-Based Criteria: How should the presence, type and proportion of ingredients influence classification?
  • Processing Methods: What physical, biological, chemical or other processes should be considered indicative of ultra-processing?
  • Terminology: Is “ultra-processed” the most appropriate term, or should alternative terminology be considered?
  • Nutritional and Other Attributes: Should factors like nutritional composition, energy density or palpability be incorporated into the definition?
  • Policy Implications: How might a standardized definition be integrated into food and nutrition policies and programs?

In addition to developing a uniform definition, FDA and the National Institutes of Health (NIH) are advancing research to investigate the health impacts of UPFs through a recently announced Nutrition Regulatory Science Program.

The RFI presents an opportunity for stakeholders to submit feedback as the administration considers policies related to UPFs. A 60-day comment period is provided, and with publication on July 25, 2025, comments are due by September 23, 2025.

Share This Insight

Previous Entries

Eye on FDA

May 19, 2026

On May 12, 2026, the Food and Drug Administration (FDA) published a notice in the Federal Register requesting comment on the agency’s efforts related to drug repurposing to help address unmet medical needs. In this request for information (RFI), FDA is seeking input to identify potential new uses for FDA-approved drugs—such as a new indication or a new population—to help accelerate the availability of treatments for unmet medical needs. Stakeholders are encouraged to submit priority disease areas and potential candidates for drug repurposing, particularly in cases where there is a lack of commercial incentive to pursue labeling changes or a significant unmet need.

...

Read More

Eye on FDA

May 14, 2026

As medical chatbots proliferate, a new Pennsylvania lawsuit highlights a developing trend of states leading health artificial intelligence (AI) enforcement efforts, while the Food and Drug Administration (FDA) appears to be on the sidelines.

...

Read More

Eye on FDA

May 13, 2026

On May 12, 2026, the U.S. Food and Drug Administration (FDA) announced a major milestone in its approach to post-market oversight of chemicals in the food supply, finalizing a new proactive food chemical safety post-market assessment program and releasing two foundational papers: the “Enhanced Systematic Process for Post-Market Assessment of Chemicals in Food” and the “Tool for the Prioritization of Food Chemicals for Post-Market Assessment.”

...

Read More

Eye on FDA

May 5, 2026

In December 2016, the bipartisan 21st Century Cures Act (P.L. 114-255) was enacted, marking a pivotal milestone in advancing a patient-focused drug development (PFDD) paradigm. This law directed the Food and Drug Administration (FDA) to develop and implement strategies to solicit view of patients during the medical product development process and consider the perspectives of patients during regulatory discussions. Over the past decade, FDA has steadily taken steps to implement the 21st Century Cures Act patient-focused drug development provisions, including through meetings by which patients, caregivers, family members and patient advocates, among others, have been able to provide information about patients’ experiences with a disease or condition. The opportunity to provide such feedback through these patient-focused meetings is a key pillar of the agency’s patient-focused drug development engagement.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.